Key Points
- Alane Barnes sold 21,773 shares on Dec. 22 at an average price of $7.65 for $166,563.45, trimming her stake by 5.18% to 398,751 shares (worth about $3.05M).
- BioCryst missed quarterly EPS expectations ($0.06 vs. $0.07) despite revenue rising 36.1% YoY, and analysts are mixed but show an average price target of $19.50 (ten Buys, three Holds, one Sell).
- Institutional investors hold a large majority of the stock (85.88% ownership); the company has a market cap of ~$1.59B and a 1‑year trading range of $6.00–$11.31.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 21,773 shares of the company's stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $7.65, for a total transaction of $166,563.45. Following the completion of the sale, the insider directly owned 398,751 shares in the company, valued at $3,050,445.15. This represents a 5.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
BioCryst Pharmaceuticals Price Performance
Shares of NASDAQ BCRX opened at $7.53 on Wednesday. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.00 and a 1 year high of $11.31. The firm has a 50-day moving average of $7.20 and a 200 day moving average of $8.05. The stock has a market cap of $1.59 billion, a P/E ratio of -150.60, a price-to-earnings-growth ratio of 0.73 and a beta of 0.91.
BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative net margin of 1.46% and a negative return on equity of 4.24%. The business had revenue of $159.40 million for the quarter, compared to the consensus estimate of $162.91 million. During the same period in the prior year, the business posted ($0.07) EPS. BioCryst Pharmaceuticals's revenue for the quarter was up 36.1% on a year-over-year basis. Research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts have commented on the company. Barclays cut their target price on BioCryst Pharmaceuticals from $11.00 to $9.00 and set an "equal weight" rating on the stock in a research note on Tuesday, November 4th. JMP Securities upped their price target on shares of BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a "market outperform" rating in a research note on Wednesday, October 15th. Needham & Company LLC reduced their price objective on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, November 4th. Cantor Fitzgerald upped their target price on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 15th. Finally, HC Wainwright increased their price target on shares of BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a "buy" rating in a report on Monday, December 15th. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $19.50.
View Our Latest Analysis on BioCryst Pharmaceuticals
Hedge Funds Weigh In On BioCryst Pharmaceuticals
A number of hedge funds have recently bought and sold shares of BCRX. Russell Investments Group Ltd. boosted its holdings in shares of BioCryst Pharmaceuticals by 269.5% during the 1st quarter. Russell Investments Group Ltd. now owns 103,329 shares of the biotechnology company's stock valued at $775,000 after acquiring an additional 75,363 shares during the last quarter. Wellington Management Group LLP lifted its position in BioCryst Pharmaceuticals by 2.6% during the first quarter. Wellington Management Group LLP now owns 91,348 shares of the biotechnology company's stock valued at $685,000 after purchasing an additional 2,291 shares during the period. AlphaQuest LLC boosted its holdings in BioCryst Pharmaceuticals by 120.3% in the first quarter. AlphaQuest LLC now owns 62,646 shares of the biotechnology company's stock worth $470,000 after purchasing an additional 34,204 shares during the last quarter. Rafferty Asset Management LLC boosted its holdings in BioCryst Pharmaceuticals by 7.9% in the first quarter. Rafferty Asset Management LLC now owns 253,325 shares of the biotechnology company's stock worth $1,900,000 after purchasing an additional 18,489 shares during the last quarter. Finally, Ieq Capital LLC grew its position in BioCryst Pharmaceuticals by 316.8% in the 1st quarter. Ieq Capital LLC now owns 122,703 shares of the biotechnology company's stock worth $920,000 after purchasing an additional 93,267 shares during the period. Hedge funds and other institutional investors own 85.88% of the company's stock.
About BioCryst Pharmaceuticals
(
Get Free Report)
BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.
The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
